Targeted therapeutics, including vascular endothelial growth factor (VEGF) suppressors and mammalian target of rapamycin (mTOR), have been accepted due to the roles in treating advanced ccRCC, and have become the standard treatment (Zhang et al., 2021a). The gene discussed is MTOR; the disease is nonpapillary renal cell carcinoma.